{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:56:14Z","timestamp":1789419374997,"version":"build-2803163510"},"reference-count":108,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":593,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.jhep.2011.06.015","type":"journal-article","created":{"date-parts":[[2011,7,25]],"date-time":"2011-07-25T08:35:33Z","timestamp":1311582933000},"page":"1441-1451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["m-TOR inhibitors: What role in liver transplantation?"],"prefix":"10.1016","volume":"55","author":[{"given":"Toshiyasu","family":"Kawahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Asthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman M.","family":"Kneteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2011.06.015_b0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00007890-199807150-00010","article-title":"Chronic renal failure following liver transplantation: a retrospective analysis","volume":"66","author":"Fisher","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0010","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0015","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/jlts.2002.35668","article-title":"Chronic renal dysfunction late after liver transplantation","volume":"8","author":"Cohen","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/SLA.0b013e3181896278","article-title":"Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence","volume":"248","author":"Vivarelli","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jhep.2011.06.015_b0025","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.molmed.2007.04.002","article-title":"MTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer","volume":"13","author":"Dann","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0030","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/00007890-199902270-00002","article-title":"Sirolimus: a potent new immunosuppressant for liver transplantation","volume":"67","author":"Watson","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0035","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0140-6736(99)03882-9","article-title":"Sirolimus\u2013tacrolimus combination immunosuppression","volume":"355","author":"McAlister","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2011.06.015_b0040","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/jlts.2000.19023","article-title":"Experience with the use of sirolimus in liver transplantation \u2013 use in patients for whom calcineurin inhibitors are contraindicated","volume":"6","author":"Chang","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0045","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/jlts.2001.23012","article-title":"Liver transplantation using sirolimus and minimal corticosteroids (3-day taper)","volume":"7","author":"Trotter","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0050","first-page":"464","article-title":"Sirolimus immunotherapy results in reduced roles of acute rejection in de novo orthotopic liver transplant recipients","volume":"2","author":"Wiesner","year":"2002","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","article-title":"TOR signaling in growth and metabolism","volume":"124","author":"Wullschleger","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2011.06.015_b0060","first-page":"2177","article-title":"Sirolimus approved with renal transplant indication","volume":"56","author":"Miller","year":"1999","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jhep.2011.06.015_b0065","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1056\/NEJMra033540","article-title":"Immunosuppressive drugs for kidney transplantation","volume":"351","author":"Halloran","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0070","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.it.2009.02.002","article-title":"The multiple facets of mTOR in immunity","volume":"30","author":"Weichhart","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jhep.2011.06.015_b0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrm3025","article-title":"MTOR: from growth signal integration to cancer, diabetes and ageing","volume":"12","author":"Zoncu","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jhep.2011.06.015_b0080","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"S\u00e4emann","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0085","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of mTOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jhep.2011.06.015_b0090","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1016\/S0021-9258(18)53755-8","article-title":"Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1\/S-phase growth arrest in T lymphocytes","volume":"268","author":"Morice","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2011.06.015_b0095","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.immuni.2009.04.014","article-title":"The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment","volume":"30","author":"Delgoffe","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.jhep.2011.06.015_b0100","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/lt.20845","article-title":"Everolimus and mTOR inhibitors in liver transplantation: opening the \u201cbox\u201d","volume":"12","author":"Everson","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0105","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.transproceed.2007.09.008","article-title":"Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy","volume":"39","author":"Chapman","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/01.TP.0000128628.31556.B1","article-title":"A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications","volume":"78","author":"Montalbano","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0115","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/hep.23835","article-title":"Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis","volume":"52","author":"Asrani","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.06.015_b0120","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1345\/aph.1E165","article-title":"Sirolimus-associated hepatotoxicity in liver transplantation","volume":"38","author":"Neff","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jhep.2011.06.015_b0125","first-page":"967","article-title":"Severe sirolimus-induced acute hepatitis in a renal transplant recipient","volume":"23","author":"Jacques","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0130","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/j.1600-6143.2010.03128.x","article-title":"Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function","volume":"10","author":"Masetti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0135","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/lt.21827","article-title":"Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial","volume":"15","author":"De Simone","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/lt.22292","article-title":"Conversion to everolimus in maintenance liver transplant patients: A multicenter retrospective analysis","author":"Saliba","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0145","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.transproceed.2009.06.087","article-title":"Indications and management of everolimus after liver transplantation","volume":"41","author":"Bilbao","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0150","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1681\/ASN.2007040394","article-title":"Chronic kidney disease after nonrenal solid-organ transplantation","volume":"18","author":"Bloom","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jhep.2011.06.015_b0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s001340050780","article-title":"Renal failure in liver disease","volume":"25","author":"Eckardt","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0025-6196(12)61034-9","article-title":"Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation","volume":"69","author":"Porayko","year":"1994","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0165","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.transproceed.2005.09.115","article-title":"Initial immunosuppression in liver transplant recipients with impaired renal function","volume":"37","author":"Varo","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0170","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1399-0012.2009.00986.x","article-title":"Relationship between renal resistance index and renal function in liver transplant recipients after cessation of calcineurin inhibitor","volume":"23","author":"Eisenberger","year":"2009","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0175","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1432-2277.2008.00796.x","article-title":"Calcineurin inhibitor minimization protocols in liver transplantation","volume":"22","author":"Farkas","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0180","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1523-1755.2005.00558.x","article-title":"Posttransplantation chronic renal damage in nonrenal transplant recipients","volume":"68","author":"Stratta","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0012.2007.00739.x","article-title":"Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity","volume":"22","author":"Flechner","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.tp.0000228921.43200.f7","article-title":"Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation","volume":"82","author":"Stephany","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0195","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/j.1432-2277.2008.00811.x","article-title":"Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy","volume":"22","author":"Neau-Cransac","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0200","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1111\/j.1600-6143.2005.01120.x","article-title":"Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat","volume":"5","author":"Daniel","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0205","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1097\/01.tp.0000282866.92367.99","article-title":"The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat","volume":"84","author":"Vogelbacher","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0210","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1432-2277.2004.tb00431.x","article-title":"Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy","volume":"17","author":"Dittrich","year":"2004","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/ndt\/gfh639","article-title":"Nephrotoxicity of rapamycin: an emerging problem in clinical medicine","volume":"20","author":"Marti","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0220","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/01.tp.0000185200.17589.74","article-title":"Proteinuria following a switch from calcineurin inhibitors to sirolimus","volume":"80","author":"Letavernier","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0225","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/ndt\/gfh079","article-title":"Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies","volume":"19","author":"Fervenza","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0230","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/lt.20707","article-title":"Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results","volume":"12","author":"Levy","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0235","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/ki.1996.417","article-title":"Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506","volume":"50","author":"Andoh","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ndt\/18.3.491","article-title":"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat","volume":"18","author":"Nielsen","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0245","first-page":"194","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study","volume":"356","author":"Kahan","year":"2000","journal-title":"The Rapamune US Study Group. Lancet"},{"key":"10.1016\/j.jhep.2011.06.015_b0250","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/lt.21116","article-title":"Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients","volume":"13","author":"Morard","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0255","first-page":"6","article-title":"Conversion to everolimus in maintenance liver transplant patients: A multicenter retrospective analysis","volume":"5","author":"Saliba","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0260","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1034\/j.1399-0012.16.s7.7.x","article-title":"Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent","volume":"16","author":"Cotterell","year":"2002","journal-title":"Clin Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0265","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1399-3046.2005.00360.x","article-title":"Replacing calcineurin inhibitors with mTOR inhibitors in children","volume":"9","author":"Sindhi","year":"2005","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0270","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.tp.0000261630.63550.41","article-title":"Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial","volume":"83","author":"Shenoy","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0275","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/lt.21314","article-title":"A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function","volume":"13","author":"Watson","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.1432-2277.2008.00768.x","article-title":"Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function","volume":"22","author":"De Simone","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0285","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0290","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0295","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1212\/WNL.45.11.1962","article-title":"Neurotoxicity in liver transplant recipients with cyclosporine immunosuppression","volume":"45","author":"Wijdicks","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2011.06.015_b0300","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/00007890-200001150-00029","article-title":"Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus","volume":"69","author":"Jain","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0305","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2165\/00003088-199630030-00001","article-title":"A new microemulsion formulation of cyclosporin: pharmacokinetic and clinical features","volume":"30","author":"Friman","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jhep.2011.06.015_b0310","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1212\/WNL.52.8.1708","article-title":"Oral cyclosporine decreases severity of neurotoxicity in liver transplant recipients","volume":"52","author":"Wijdicks","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2011.06.015_b0315","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1432-2277.2000.tb01040.x","article-title":"Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients","volume":"13","author":"Emre","year":"2000","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0320","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1212\/01.WNL.0000144351.63740.81","article-title":"Sirolimus may not cause neurotoxicity in kidney and liver transplant recipients","volume":"63","author":"Maramattom","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jhep.2011.06.015_b0325","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0025-6196(11)60541-7","article-title":"No major neurologic complications with sirolimus use in heart transplant recipients","volume":"84","author":"van de Beek","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0330","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/j.1432-2277.2006.00381.x","article-title":"Sirolimus as the main immunosuppressant in the early postoperative period following liver transplantation: a report of six cases and review of the literature","volume":"19","author":"Vivarelli","year":"2006","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhep.2011.06.015_b0335","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/lt.21123","article-title":"Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States","volume":"13","author":"Thuluvath","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0340","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/lt.500060111","article-title":"Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity","volume":"6","author":"Pelletier","year":"2000","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0345","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0168-8278(00)80231-7","article-title":"HCV-related fibrosis progression following liver transplantation: increase in recent years","volume":"32","author":"Berenguer","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.06.015_b0350","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2006.01.005","article-title":"Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression","volume":"44","author":"Berenguer","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.06.015_b0355","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/lt.21035","article-title":"Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis","volume":"13","author":"Berenguer","year":"2007","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0360","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/lt.20532","article-title":"Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation","volume":"12","author":"Firpi","year":"2006","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0365","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1053\/jhep.2003.50449","article-title":"Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes","volume":"38","author":"Watashi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.06.015_b0370","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1053\/j.gastro.2005.06.031","article-title":"Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins","volume":"129","author":"Nakagawa","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2011.06.015_b0375","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1016\/j.transproceed.2007.08.086","article-title":"Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study","volume":"39","author":"Guitard","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0380","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/TP.0b013e3181fa93fa","article-title":"Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients","volume":"90","author":"Berenguer","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0385","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2006.07.030","article-title":"Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis","volume":"45","author":"Neef","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2011.06.015_b0390","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.1128\/JVI.79.14.8742-8749.2005","article-title":"Activation of the N-Ras-PI3K-Akt-mTOR pathway by hepatitis C virus: control of cell survival and viral replication","volume":"79","author":"Mannov\u00e1","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2011.06.015_b0395","doi-asserted-by":"crossref","first-page":"20870","DOI":"10.1074\/jbc.M110.112045","article-title":"Hepatitis C virus NS5A activates the mammalian target of rapamycin (mTOR) pathway, contributing to cell survival by disrupting the interaction between FK506-binding protein 38 (FKBP38) and mTOR","volume":"285","author":"Peng","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2011.06.015_b0400","doi-asserted-by":"crossref","first-page":"11836","DOI":"10.1074\/jbc.M610106200","article-title":"P21-activated kinase 1 is activated through the mammalian target of rapamycin\/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells","volume":"282","author":"Ishida","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2011.06.015_b0405","doi-asserted-by":"crossref","first-page":"6060","DOI":"10.1128\/JVI.02484-09","article-title":"Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner","volume":"84","author":"Shao","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2011.06.015_b0410","doi-asserted-by":"crossref","first-page":"193S","DOI":"10.1016\/S0041-1345(03)00234-3","article-title":"Sirolimus in liver transplantation","volume":"35","author":"Trotter","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0415","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.intimp.2010.05.006","article-title":"Sirolimus has a potential to influent viral recurrence in HCV positive liver transplant candidates","volume":"10","author":"Wagner","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jhep.2011.06.015_b0420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1155\/2011\/201019","article-title":"The impact of sirolimus on hepatitis C recurrence after liver transplantation","volume":"25","author":"Asthana","year":"2011","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2011.06.015_b0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00007890-201007272-00241","article-title":"Limiting HCV progression in transplant recipients through conversion to sirolimus based immunosuppression","volume":"90","author":"McKenna","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0430","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00007890-201007272-00237","volume":"90","author":"Asthana","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0435","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/lt.20237","article-title":"Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma","volume":"10","author":"Kneteman","year":"2004","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0440","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/01.tp.0000262607.95372.e0","article-title":"De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects","volume":"83","author":"Toso","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0445","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2011.06.015_b0450","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00007890-199902270-00003","article-title":"Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma","volume":"67","author":"Freise","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0455","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/1097-0142(19911115)68:10<2095::AID-CNCR2820681002>3.0.CO;2-Y","article-title":"Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation","volume":"68","author":"Yokoyama","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2011.06.015_b0460","first-page":"3579","article-title":"Pattern of recurrence of hepatocellular carcinoma after liver transplantation: Milan multicenter experience","volume":"26","author":"Regalia","year":"1994","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0465","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/lt.20391","article-title":"Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression","volume":"11","author":"Vivarelli","year":"2005","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0470","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0041-1345(02)02899-3","article-title":"Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth","volume":"34","author":"Schumacher","year":"2002","journal-title":"Transplant Proc"},{"key":"10.1016\/j.jhep.2011.06.015_b0475","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0480","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1182\/blood-2004-09-3540","article-title":"Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF","volume":"105","author":"Guba","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2011.06.015_b0485","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"MTOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.jhep.2011.06.015_b0490","doi-asserted-by":"crossref","first-page":"7215","DOI":"10.1158\/1078-0432.CCR-06-2254","article-title":"Targeting von Hippel-Lindau pathway in renal cell carcinoma","volume":"12","author":"Patel","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2011.06.015_b0495","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa042831","article-title":"Sirolimus for Kaposi\u2019s sarcoma in renal-transplant recipients","volume":"352","author":"Stallone","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2011.06.015_b0500","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0505","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1600-6143.2009.02997.x","article-title":"Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial","volume":"10","author":"Salgo","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2011.06.015_b0510","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1097\/01.TP.0000154913.88193.FF","article-title":"Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil","volume":"79","author":"Elsharkawi","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0515","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/lt.21420","article-title":"Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"15","author":"Zimmerman","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0520","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3748\/wjg.v12.i19.3114","article-title":"Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience","volume":"12","author":"Zhou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2011.06.015_b0525","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/TP.0b013e3181c3c540","article-title":"Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma","volume":"89","author":"Vivarelli","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2011.06.015_b0530","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1002\/lt.21953","article-title":"Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation","volume":"15","author":"Chinnakotla","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhep.2011.06.015_b0535","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/hep.23437","article-title":"Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma","volume":"51","author":"Toso","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2011.06.015_b0540","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-10-190","volume":"10","author":"Schnitzbauer","year":"2010","journal-title":"BMC Cancer"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811005174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827811005174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:34:00Z","timestamp":1759174440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827811005174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S0168827811005174"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2011.06.015","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"m-TOR inhibitors: What role in liver transplantation?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2011.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 European Association for the Study of the Liver. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}